Brand name · Buprenorphine hydrochloride and naloxone hydrochloride
Zubsolv: adverse event reports filed with FDA
973 reports list it as a suspect or interacting product, 2013–2026. Class: Opioid antagonist.
- 973
- reports as suspect product
- 0% of all reports · about 77 a year
- 44
- reports, 12 months to June 2026
- 58 in the 12 months before
- 21%
- marked serious by the reporter
- 62.4% across the class
- 0.6%
- record death among outcomes, as reported
- 6 reports · not verified by FDA
973 adverse event reports received by FDA list the brand name Zubsolv (buprenorphine hydrochloride and naloxone hydrochloride) as a suspect or interacting product, from November 2013 to June 2026. A further 109 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 44 reports listed it, down 24% from 58 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 77 reports a year and 0% of the 20,646,523 reports in the database, and 3.1% of the reports for the opioid antagonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are nausea (11%), wrong technique in product usage process (10.1%) and drug withdrawal syndrome (9.7%). A report can list several reactions, so shares add to more than 100%; 187 different terms appear across these reports. Nausea is recorded in 11% of these reports, a larger share than in the median opioid antagonist drug (6.4%).
21% of the reports are marked serious by the reporter (62.4% across the class); 0.6% record death among the outcomes and 4.3% record hospitalisation, as reported. 57.2% of the reports came from consumers, and the largest patient age group is 18 to 44 (23.9%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Zubsolv reports recording the termmedian drug in opioid antagonist
- Nauseafeeling sick11%107
- Wrong technique in product usage processthe product was used in the wrong way10.1%98
- Drug withdrawal syndromesymptoms on stopping a medicine9.7%94
- Vomitingbeing sick7.3%71
- Headachehead pain7.2%70
- Drug dependencedependence on a medicine6.3%61
- Off label useused for a purpose or in a way not on the label6.1%59
- Drug ineffectivethe medicine did not work as expected6%58
- Feeling abnormalfeeling odd or not right5.8%56
- Malaisegeneral feeling of being unwell4.8%47
- Withdrawal syndrome4.6%45
- Anxietyanxiety4%39
- Hyperhidrosisexcessive sweating3.9%38
- Product use in unapproved indicationused for a purpose not on the label3.5%34
- Inappropriate schedule of product administrationthe product was taken at the wrong times3.4%33
- Dental caries3.2%31
- Insomniadifficulty sleeping3%29
- Product use issuea problem in how the product was used3%29
- Dizzinesslight-headedness or unsteadiness2.8%27
- Fatiguetiredness2.7%26
- Painpain, site not specified2.7%26
- Abdominal pain upperupper stomach pain2.2%21
- Depressionlow mood2.2%21
- Diarrhoealoose or frequent stools2.1%20
- Dyspnoeashortness of breath2.1%20
- Product substitution issuea problem after switching products2.1%20
- Astheniaweakness or lack of energy2%19
- Tremorshaking2%19
- Drug effect incomplete1.8%18
- Rashskin rash1.8%18
Top 30 of 187 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 10 drugs in the opioid antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 31,239 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.7% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Drug dependence | 324 | 33.3% |
| Pain | 85 | 8.7% |
| Drug use disorder | 60 | 6.2% |
| Dependence | 10 | 1% |
| Drug withdrawal syndrome | 7 | 0.7% |
| Back pain | 6 | 0.6% |
The indication field is filled in by the reporter and is often blank; shares are of all 973 reports.
In context
| Measure | Zubsolv | Opioid antagonist | All reports |
|---|---|---|---|
| Reports as suspect product | 973 | 31,239 | 20,646,523 |
| Share of that pool | — | 3.1% | 0% |
| Reports, latest 12 months | 44 | — | 1,332,454 |
| Marked serious | 21% | 62.4% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 6 | 87 | 91 |
| Hospitalisation recorded, per 1,000 reports | 43 | 204 | 213 |
| Consumer-filed share | 57.2% | 48.6% | 45.8% |
| Top term, share of reports | Nausea 11% | median 6.4% | 3.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the opioid antagonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Suboxone | brand | 20,919 | 552 | 66.8% |
| Movantik | brand | 1,997 | 45 | 26.9% |
| Buprenorphine and naloxone | generic | 1,935 | 66 | 53.7% |
| Naloxone | generic | 1,693 | 129 | 94.2% |
| Relistor | brand | 978 | 28 | 55.4% |
| Narcan | brand | 835 | 38 | 56.2% |
| Buprenorphine hydrochloride, naloxone hydrochloride | generic | 824 | 77 | 57.9% |
| Symproic | brand | 548 | 13 | 47.3% |
| Naloxone hydrochloride | generic | 537 | 61 | 73.4% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Zubsolv reports
How many adverse event reports has FDA received for Zubsolv?
973 reports list Zubsolv as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 44 of them arrived in the latest 12 months. Another 109 list it only as a concomitant medication.
What reactions are recorded in Zubsolv reports?
nausea (11%), wrong technique in product usage process (10.1%), drug withdrawal syndrome (9.7%), vomiting (7.3%) and headache (7.2%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Zubsolv was responsible.
How serious are the reports?
21% are marked serious by the reporter. Among the outcomes recorded, 0.6% of reports include death and 4.3% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (57.2%), physician (16.8%) and other health professional (11.9%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Zubsolv rising?
44 reports in the 12 months to June 2026, down 24% from 58 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Zubsolv was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Zubsolv?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zubsolv as a suspect or interacting product; reports listing it only as a concomitant medication (109) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.